Novo's obesity business and Chinese challenges will be examined closely, says analyst

A new insulin supply model in China is expected to affect sales next year, and this challenge combined with Novo Nordisk's sales figures for obesity drugs will be ABG Sundal Collier's main focus when the Danish pharmaceutical company releases its financial report tomorrow.

Photo: Novo Nordisk / PR

Novo Nordisk's obesity business and the insulin sales prospects in China could take center stage when the Danish pharmaceutical company releases its quarterly report Wednesday morning.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs